Johannes Bloehdorn

TL;DR: Unmutated CLL derives from unmutated mature CD5+ B cells and mutated CLL derived from CD5 +CD27+ post–germinal center B cells.

TL;DR: Venetoclax achieves durable responses and was well tolerated in patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia and a high rate of blood MRD < 10-4 was achieved in this high-risk population.

TL;DR: A retrospective cohort study of all patients with MCL who experienced disease progression while receiving ibrutinib across 15 international sites, poor clinical outcomes were noted in the majority of patients with primary or secondary ibrUTinib resistance and treatments could not identify treatments that clearly improved outcomes.

TL;DR: There were characteristic modes of discordance between ZAP-70 and VH mutation status depending on the presence or absence of additional genetic high-risk features such as 11q and 17p deletion or V3-21 usage.

TL;DR: To identify genomic alterations in chronic lymphocytic leukemia (CLL), single-nucleotide polymorphism-array analysis using Affymetrix Version 6.0 on 353 samples from untreated patients entered in the CLL8 treatment trial revealed copy number alterations and a truncating mutation in one CLL patient lacking a 15q deletion.